Pharminox' internal drug discovery and in-licensing activities are target-driven and based on world-class medicinal chemistry, drug development and commercial expertise brought by an experienced team led by CEO Peter Worrall (ex Vernalis, British Biotech), CSO Professor Malcolm Stevens (former Director of the Cancer Research UK Experimental Cancer Chemotherapy Group) and Head of Chemistry Marc Hummersone (ex KuDOS Pharmaceuticals).

Since its formation in 2002, Pharminox has built a pipeline of proprietary anti-cancer programmes spanning early stage discovery through to clinical development, and has also established a broad collaboration with Schering Plough.